Did You Know...
...that the video game, Pong, was invented by a guy who graduated at the bottom of his engineering class? Nolan Bushnell spent more time running the games at a local amusement park than he did on his studies at the University of Utah. His dreams of working for Disney's amusement empire were dashed when the company wouldn't hire him. Taking a boring job, Nolan daydreamed about electronic versions of popular games. He invented Pong, the first video game, and went on to found Atari Co.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7528112 | Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders A synthetic peptide sequence demonstrating neuroprotective and anti-inflammatory functions is disclosed. Methods of use for the synthetic peptide are also provided. ... | 05/05/2009 |
| 7521425 | Anti-angiogenic compounds The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angi... | 04/21/2009 |
| 7507718 | Polymyxin B analogs for LPS detoxification The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and therefore to detoxify LPS. The dimeric structure is maintained by a pair ... | 03/24/2009 |
| 7498309 | Pharmaceutical compositions for bioactive peptide agents Disclosed are pharmaceutical compositions suitable for oral administration of bioactive peptides. Particularly, the pharmaceutical compositions comprise peptides formulated as suspensions stabilized with a dispersing agent. The compositions may be encapsulated in ca... | 03/03/2009 |
| 7494980 | Antimicrobial peptide and methods of use thereof A method of preventing biofilm formation in an environment including the steps of administering to the environment an effective amount of a peptide having the amino acid sequence NH2-lys-lys-val-val-phe-lys-val-lys-phe-lys-CONH2 [SEQ ID NO: 1] ... | 02/24/2009 |
| 7488718 | Synthetic HLA binding peptide analogues and uses thereof The present invention provides synthetic peptides comprising at least analogues of a native peptide that specifically bind to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state, such as a cancer cell, in a mammal. Also provided are... | 02/10/2009 |
| 7479484 | Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity The invention provides compounds having immune-modulating and/or anti-inflammatory and/or anti-viral activity, wherein compounds of the invention include peptides and peptidomimetics. The invention further provides methods of using immune-modulating and/or anti-infl... | 01/20/2009 |
| 7476657 | Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compo... | 01/13/2009 |
| 7468353 | Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung diseases The invention describes for the first time the preclinical/cellular and clinical relevance of VIP, PACAP as well as of substances with the same biological activity as VIP and PACAP for the treatment of interstitial lung infections such as idiopathic pulmonary fibros... | 12/23/2008 |
| 7459442 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof The present invention provides compounds represented by the structural formula (I): or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as sp... | 12/02/2008 |
| 7456153 | Compounds and methods for modulating functions of classical cadherins Modulating agents and methods for enhancing or inhibiting classical cadherin-mediated functions are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of a classical cadherin molecule, a conservative analogue... | 11/25/2008 |
| 7446095 | Peptides modulating caspase activation The present invention provides structures of small molecules capable of modulating apoptotic cell death. More specifically, the structures relate to the structures of apoptotic active sites of mammalian alpha-fetoprotein (AFP) and albumin. Peptides mimicking the act... | 11/04/2008 |
| 7439228 | Bioactive peptides The present invention provides a cytotoxic 7 to 25-mer peptide with three or more catonic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the... | 10/21/2008 |
| 7438890 | Binding peptides for carcinoembryonic antigen (CEA) The present invention provides binding moieties for CEA, which have a variety of uses wherever detecting, isolating or localizing CEA, and particularly CEA as opposed to cross-reactive antigens such as NCA, is advantageous. Particularly disclosed are synthetic, isol... | 10/21/2008 |
| 7435721 | Transport peptides such as C-terminal Epeptide and analogues thereof The invention relates to peptides derived from or similar to the Erns protein of pestiviruses for type-specific diagnosis of infection, for eliciting antibiotic activity, and for transport of substances into a cell. For these purposes, the invention provi... | 10/14/2008 |
| 7435716 | Compounds pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia Novel conjugates of bacterial outer membrane binding peptides, preferably having bacterial sensitization activity, and immune cells chemotactic peptides, and pharmaceutical compositions containing same useful in the treatment of bacteremia and/or septicemia followin... | 10/14/2008 |
| 7427590 | Neurothrophic components of the ADNF I complex This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceu... | 09/23/2008 |
| 7427598 | Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory The present invention provides methods for improving performance (e.g. learning and/or memory) using (ADNF) polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to i... | 09/23/2008 |
| 7425541 | Enzyme-cleavable prodrug compounds The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are m... | 09/16/2008 |
| 7417028 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP ... | 08/26/2008 |
| 7414029 | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus... | 08/19/2008 |
| 7407938 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable... | 08/05/2008 |
| 7404948 | Peptidic conjugates for alopecia prevention and treatment The invention relates to novel peptidic conjugates containing a Gly-His-Lys sequence and used for dermatology or cosmetology for stimulating hair growth or stopping hair fall. ... | 07/29/2008 |
| 7405200 | Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis A method of treating cancer in situ and cervicitis is disclosed. A pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis and compound of the formula SEQ ID NO:2 is also disclosed. ... | 07/29/2008 |
| 7402558 | Method for aiding implantation or decreasing miscarriage rate The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG or LH, or a bio-analogue thereof, is administered during the follicular phase. ... | 07/22/2008 |
| 7402560 | NCAM binding compounds The invention provides novel compounds which are capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM). Additionally, the invention relates to methods for treatment of normal, degenerated and dam... | 07/22/2008 |
| 7399747 | Peptides carrying substances across the blood brain barrier The invention concerns the use of a linear peptide paired with an active substance for diagnosing or treating a CNS pathology by preparing a medicine capable of crossing the blood brain barrier to be used for diagnosis or treatment of a pathology localized in the CN... | 07/15/2008 |
| 7396816 | Low-molecular weight peptides inhibiting ion channel activity It is intended to provide novel polypeptides which specifically inhibit the activity of a mechano-sensitive channel; and mechano-sensitive channel inhibitors or remedies for atrial fibrillation containing these polypeptides or salts thereof. The above objects can be... | 07/08/2008 |
| 7393834 | LHRH-antagonists in the treatment of fertility disorders A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selecti... | 07/01/2008 |
| 7390873 | Antimicrobial cationic peptides A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X1X1PX2X... | 06/24/2008 |
| 7387998 | STQ peptides The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antago... | 06/17/2008 |
| 7388071 | Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells. ... | 06/17/2008 |
| 7384908 | Orally active peptides that prevent cell damage and death This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active ... | 06/10/2008 |
| 7378396 | Therapeutic agents and methods for cardiovascular disease The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (... | 05/27/2008 |
| 7378384 | WT1 substitution peptides Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. | 05/27/2008 |
| 7375079 | Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins The compounds of the invention are generally described by the formula: B1Z*2B3Z*4X*5Q6F7X8X9X10X11, (1) B1X | 05/20/2008 |
| 7371727 | Methods and compositions for the treatment of gastrointestinal disorders The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogas... | 05/13/2008 |
| 7371728 | Prostate-specific antigen probes for optical imaging This invention provides a novel probe, which contains a prostate peptide substrate. The probe can be used as a prostate diagnostic agent for optical imaging. An 11 amino acid peptide substrate is synthesized for specific prostate-specific antigen (PSA). This protect... | 05/13/2008 |
| 7368432 | Conotoxin peptides The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably i... | 05/06/2008 |
| 7368431 | Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon The inventive polypeptide is embodied in the form of a similar fragment of the epidermal growth factor of aminoacid ranging from 21 to 31 and capable of efficiently binding with the receptor of the epidermal growth factor as a vector for the directed supply of antic... | 05/06/2008 |
